CHICAGO — Erdafitinib improved OS, PFS and objective response rate compared with chemotherapy among patients with advanced or metastatic urothelial cancer with select fibroblast growth factor receptor alterations. Results of the phase 3 THOR trial, presented at ASCO Annual Meeting 2023, showed the FGFR inhibitor reduced the risk for death by 36% among the patient population compared with
Confirmatory data from Cohort 1 of the Phase 3 THOR study showed greater than four-month improvement in median overall survival in patients treated with.
Erdafitinib reduced the risk of death by 36% vs investigator’s choice of chemotherapy in patients with FGFR2/3-altered metastatic urothelial cancer who were previously treated with anti–PD-1 therapy, according to findings from the phase 3 THOR trial.